Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053201 | 0.87 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DCA12 | |
| SCHEMBL6605487 | 0.86 | NPC1 (0.38) | PDE4APDE4BPDE4CPDE4DTDP1 | |
| SCHEMBL7050225 | 0.84 | PDE4D (0.62) | PDE4APDE4BPDE4CPDE4DCA12 | |
| SCHEMBL7433190 | 0.83 | PDE4D (0.41) | PDE4APDE4BPDE4CPDE4DCA12 | |
| SCHEMBL3924757 | 0.83 | KDM4E (0.49) | PDE4APDE4BPDE4CPDE4DCA12 | |
| SCHEMBL3931673 | 0.83 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DCA12 | |
| SCHEMBL3922215 | 0.82 | PPARG (0.44) | PDE4APDE4BPDE4CPDE4DCA12 | |
| SCHEMBL7365432 | 0.80 | PDE4D (0.43) | PDE4APDE4BPDE4CPDE4DCA12 | |
| SCHEMBL73952 | 0.80 | ALDH1A1 (0.47) | PDE4APDE4BPDE4CPDE4DCA12 | |
| SCHEMBL7420398 | 0.79 | PDE4D (0.39) | PDE4APDE4BPDE4CPDE4DCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257548-B1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2004-05-06 | — | — | EP | claimed |
| EP-1257548-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 2002-11-20 | — | — | EP | claimed |
| US-6331556-B2 | BENZOFURAN-4-CARBOXYLIC ACID AMIDE DERIVATIVES USED AS PHOSPHODIESTERASE IV OR TUMOR NECROSIS FACTOR INHIBITORS | DARWIN DISCOVERY, LTD. (GB) | 2001-12-18 | — | — | US | claimed |
| US-20010031777-A1 | Heterocyclic compounds and their therapeutic use | DARWIN DISCOVERY LIMITED (GB) | 2001-10-18 | — | — | US | claimed |
| WO-2001058895-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 2001-08-16 | — | — | WO | claimed |
| EP-1257548-B1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2004-05-06 | — | — | EP | disclosed |
| EP-1257548-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 2002-11-20 | — | — | EP | disclosed |
| US-6455561-B1 | ADMINISTERING BENZOFURAN DERIVATIVE FOR THERAPY OF DISEASE STATE THAT IS CAPABLE OF BEING MODULATED BY INHIBITION OF PHOSPHODIESTERASE IV OR TUMOUR NECROSIS FACTOR | DARWIN DISCOVERY, LTD. (GB) | 2002-09-24 | — | — | US | disclosed |
| US-20020022645-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-02-21 | — | — | US | disclosed |
| US-6331556-B2 | BENZOFURAN-4-CARBOXYLIC ACID AMIDE DERIVATIVES USED AS PHOSPHODIESTERASE IV OR TUMOR NECROSIS FACTOR INHIBITORS | DARWIN DISCOVERY, LTD. (GB) | 2001-12-18 | — | — | US | disclosed |
| US-20010031777-A1 | Heterocyclic compounds and their therapeutic use | DARWIN DISCOVERY LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| WO-2001058895-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031777-A1 | Heterocyclic compounds and their therapeutic use | CYP2F1, CYP11B2, CYP3A7 | PDE4A 3177/4885PDE4B 2238/4885PDE4C 2818/4885 |
| US-20020022645-A1 | Heterocyclic compounds and their therapeutic use | EPX, MPO, PDE3B | PDE4A 12/4885PDE4B 8/4885PDE4C 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.